DIABETES METAB:中国CDC发布糖尿病负担地图:东北、西北负担最重,近30年国人因血糖高死亡率增加了60%

2018-11-01 卢芳 中国循环杂志

中国是全球头号糖尿病大国:每4位糖尿病患者中就有1位来自中国。

中国是全球头号糖尿病大国:每4位糖尿病患者中就有1位来自中国。

根据全国调查数据,2002年成人糖尿病患病率估计为2.6%,仅仅5年后,2007年迅速增加到9.7%,2013年增长为10.9%。2016年,约9千万国人患糖尿病。

近期中国疾控中心(CDC)周脉耕等通过分析1990~2016年糖尿病及高空腹血糖的疾病负担发现:中青年(15~49岁)糖尿病患病率迅猛增加。

作者称,同西方国家相比,中国糖尿病蔓延速度快、相对早发而且糖尿病的知晓率和治疗率都较低。

研究显示,2016年,有14万人死于糖尿病,其中51%是男性。糖尿病和糖尿病肾病死亡率分别增加了63.5%和33.3%。糖尿病年龄标准化死亡率从1990年的10.8/10万人上升到2000年的13.2/10万人,2016年回落到10.0/10万人。

在1990~2006年,归因于高空腹血糖的死亡率增加了59.5%,从41.9/10万人上升到66.9/10万人。主要体现在缺血性心脏病、脑卒中和糖尿病。

值得注意的是,糖尿病和糖尿病肾病死亡率在15~49岁的糖尿病患者中增加更快。

作者特别指出,中国吃的大部分谷物都是精制的,如白米和精制面粉,使饮食中的血糖负荷过重,从而导致糖尿病风险增加。

1990~2016年期间,糖尿病所致伤残调整生命年(DALY)上升了95%,但年龄标准化DALY上升了2.3%,作者认为这与人口增长和老龄化有关。

2016年,我国糖尿病疾病负担最高的地区集中在东北和西北,天津、新疆、辽宁省尤为突出,标化DALY率超过了600人年/10万,其中天津市最高达696.1人年/10万;香港、湖北和浙江省最低,其中香港为279.5人年/10万。

从地区来看,这26年来,14个省份糖尿病所致年龄标准化DALY下降,但在19个省份却增加。其中下降最快的是香港、广东省和福建省,而北京、青海省和山东省增长最快。

2016年,空腹血糖成为国人DALY第6位危险因素,导致的DALY损失达1802.3/10万人。

糖尿病的蔓延,是生物进化与当今外界环境间不协调的结果。而中国经济飞速发展,城市化进程加快,使得人们的生活方式、饮食习惯都有较大变化。

研究显示,肥胖,全谷物、坚果和种子类食物的摄入减少是当前糖尿病的最重要危险因素。

为遏制糖尿病,目前健康中国2030以及《中国防治慢性病中长期规划(2017~2025年)》等已经开始落地。全民健康生活方式行动等项目也已行动。

曾经一篇发表在lancet上的文章指出,如果想让中国的所有糖尿病患者得到国家出钱的常规护理,那么花费可能会占到中国医疗保健开支的一半以上。

研究者也强调,防控糖尿病和高血糖症,不仅可改善公众健康,也是促进中国经济可持续发展的重要举措。

这项研究中,研究者根据全球疾病负担2016(GBD2016)的分析策略,就1990~2016年全国33个省市糖尿病和高空腹血糖的疾病负担进行了分析。

原始出处:
Liu M, Liu SW, Wang LJ, et al. Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to 2016, global burden of disease study. Diabetes Metab. 2018 Sep 6. doi:10.1016/j.diabet.2018.08.008.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1902156, encodeId=aa841902156d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 27 09:26:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760878, encodeId=e2a71e6087888, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 13:26:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887958, encodeId=cd63188e9581b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 17 13:26:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896414, encodeId=d300189641462, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 16 01:26:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638838, encodeId=972416388382f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 28 17:26:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042008, encodeId=d5b7104200822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 21:26:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1902156, encodeId=aa841902156d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 27 09:26:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760878, encodeId=e2a71e6087888, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 13:26:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887958, encodeId=cd63188e9581b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 17 13:26:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896414, encodeId=d300189641462, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 16 01:26:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638838, encodeId=972416388382f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 28 17:26:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042008, encodeId=d5b7104200822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 21:26:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1902156, encodeId=aa841902156d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 27 09:26:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760878, encodeId=e2a71e6087888, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 13:26:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887958, encodeId=cd63188e9581b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 17 13:26:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896414, encodeId=d300189641462, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 16 01:26:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638838, encodeId=972416388382f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 28 17:26:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042008, encodeId=d5b7104200822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 21:26:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-10-17 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1902156, encodeId=aa841902156d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 27 09:26:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760878, encodeId=e2a71e6087888, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 13:26:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887958, encodeId=cd63188e9581b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 17 13:26:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896414, encodeId=d300189641462, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 16 01:26:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638838, encodeId=972416388382f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 28 17:26:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042008, encodeId=d5b7104200822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 21:26:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-03-16 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1902156, encodeId=aa841902156d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 27 09:26:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760878, encodeId=e2a71e6087888, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 13:26:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887958, encodeId=cd63188e9581b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 17 13:26:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896414, encodeId=d300189641462, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 16 01:26:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638838, encodeId=972416388382f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 28 17:26:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042008, encodeId=d5b7104200822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 21:26:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1902156, encodeId=aa841902156d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 27 09:26:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760878, encodeId=e2a71e6087888, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 13:26:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887958, encodeId=cd63188e9581b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 17 13:26:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896414, encodeId=d300189641462, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 16 01:26:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638838, encodeId=972416388382f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 28 17:26:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042008, encodeId=d5b7104200822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 21:26:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

盘点:肥胖近期重要研究一览

【1】JAMA Oncol:女性肥胖与结直肠癌风险增加93%有关 来自华盛顿大学医学院的Yin Cao学者及其同事对85256名年龄在25岁-44岁之间的女性进行了22年的随访,探究体质指数(BMI)和结直肠癌风险之间的关系。结果发现,对于50岁以下的中青年群体,BMI≥30与结直肠癌风险增加93%有关!BMI每增加5个单位,与结直肠癌风险增加20%有关! 在这项研究中,研究人员使

糖尿病患者要注意的8大饭后禁忌

糖尿病是最常见的慢性病之一,随着人们生活水平的提高,人口老龄化以及肥胖发生率的增加,糖尿病的发病率呈逐年上升趋势。糖尿病的治疗要以稳定血糖为主,不仅是改善胰岛素的分泌状况,还要控制饮食方面对于糖类的摄入。活中人们要注意了解糖尿病治疗方法,避免糖尿病的进一步恶化。

Diabetic Med: 16年来初级保健中结构化糖尿病护理计划的绩效趋势?

近日,国际杂志 《Diabetic Med》上在线发表一项关于16年来初级保健中结构化糖尿病护理计划的绩效趋势的社区质量研究。调查1999 - 2016年为2型糖尿病患者提供的结构性初级保健主导计划的护理质量。 米德兰糖尿病结构护理计划时提供结构化的初级护理管理。检查护理过程中随时间变化的趋势(使用卡方趋势检验和年龄和性别校正的逻辑回归)并调查了筛选和年度审查出勤情况。由八个国家健康和护理

Diabetic Med:持续血糖监测会导致马来西亚胰岛素治疗的妊娠期糖尿病患者的HbA 1c水平降低?

近日,国际杂志 《Diabetic Med》上在线发表一项持续血糖监测会导致马来西亚胰岛素治疗的妊娠期糖尿病患者的HbA 1c水平降低随机对照试验的研究。研究目的是确定治疗性,回顾性的连续血糖监测(CGM)是否能改善低血糖发生较少的胰岛素治疗的妊娠期糖尿病(GDM)患者的HbA 1c。 这是一项前瞻性,随机对照,开放标签试验,共计评估了50名接受胰岛素治疗的GDM女性,随机分成在妊娠28,

Diabetic Med:医疗保健专业人士的态度在糖尿病自我管理教育的吸收中起着重要作用

近日,国际杂志 《Diabetic Med》上在线发表一项关于医疗保健专业人士的态度在糖尿病自我管理教育的吸收中起着重要作用,探讨在成人1型糖尿病患者中对认可的糖尿病自我管理教育(DSME)的接受不良的原因。 该研究是在英国南伦敦的一个城市人口中进行的。横断面调查收集了人口统计,糖尿病服务使用数据,心理评分和不参加当地DSME的原因。此外,还调查了56名医疗保健专业人员。 研究显示,

Diabetic Med:使用医疗点HbA 1c测量来估计丹麦维堡市心血管筛查项目中67岁参与者中未确诊糖尿病的水平

近日,国际杂志 《Diabetic Med》上在线发表一项关于使用即时HbA 1c测量来估计丹麦维堡市心血管筛查项目中67岁参与者中未确诊糖尿病的水平的研究。以确定丹麦67岁老人参与针对心血管疾病和糖尿病的筛查计划中未识别糖尿病的患病率,并根据医疗点HbA 1c结合自我报告的糖尿病描述个体的血糖水平状态。 在这项以人口为基础的回顾性研究中,所有居住在维堡市的67岁人士都被邀请参加Vibor